IMR Press / FBL / Volume 16 / Issue 7 / DOI: 10.2741/3884

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Article
Alternative splicing of RAGE: roles in biology and disease
Show Less
1 Division of Nephrology/Hypertension, Feinberg School of Medicine, Northwestern University, IL, USA
2 Department of Medicine and Pharmacology, NYU Langone Medical Center, NY, USA
3 Division of Endocrinology, Diabetes and Metabolism, Miller School of Medicine, University of Miami, FL, USA
Academic Editor:Li Lin
Front. Biosci. (Landmark Ed) 2011, 16(7), 2756–2770; https://doi.org/10.2741/3884
Published: 1 June 2011
(This article belongs to the Special Issue RAGE signaling)
Abstract

The Receptor for Advanced Glycation End-products (RAGE) is a complex, multi-ligand signaling system implicated in the pathogenesis of diabetes, cardiovascular disease and various cancers. RAGE undergoes extensive alternative splicing to produce a variety of transcripts with diverse functions, including soluble antagonists and variants with altered ligand binding domains. Studies focused on the major soluble variant (RAGEv1/esRAGE) have revealed this to function by binding RAGE-ligands and preventing activation of RAGE signaling in vascular and tumor cells. Furthermore, measurement of this variant in human serum has revealed that RAGEv1/esRAGE levels may represent a novel biomarker for RAGE-ligand related pathogenic states. Understanding the full plethora of RAGE alternative splicing and its regulation is central to elucidating the role of RAGE in biology and disease.

Share
Back to top